Abrysvo is a vaccine for protecting against lower respiratory tract disease (LRTD; diseases of the lungs such as bronchitis or pneumonia) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. It is also for use in mothers during pregnancy to protect their infants against LRTD from birth through 6 months of age. Abrysvo contains versions of two proteins found on the surface of the virus called RSV subgroup A stabilised prefusion F and RSV subgroup B stabilised prefusion F.
Therapeutic Indication
### Therapeutic indication Abrysvo is indicated for: - Passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy. See sections 4.2 and 5.1. - Active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV. The use of this vaccine should be in accordance with official recommendations.
Therapeutic Area (MeSH)
N/AATC Code
J07BX05
ATC Item
respiratory syncytial virus vaccines
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Respiratory Syncytial Virus, subgroup A, stabilized prefusion F protein 847A / Respiratory syncytial virus, subgroup B, stabilized prefusion F protein 847B | N/A | respiratory syncytial virus, subgroup a, stabilized prefusion f protein 847 a / respiratory syncytial virus, subgroup b, stabilized prefusion f protein 847 b |
| Respiratory syncytial virus, subgroup A, stabilized prefusion F protein 847A / Respiratory syncytial virus, subgroup B, stabilized prefusion F protein 847B | N/A | respiratory syncytial virus, subgroup a, stabilized prefusion f protein 847 a / respiratory syncytial virus, subgroup b, stabilized prefusion f protein 847 b |
EMA Name
Abrysvo
Medicine Name
Abrysvo
Aliases
N/ANo risk management plan link.
